Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone + sodium hyaluronate + tobramycin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
A combination ophthalmic preparation containing dexamethasone (a corticosteroid), sodium hyaluronate (a lubricant), and tobramycin (an antibiotic). This combination is primarily used to treat dry eye conditions after cataract surgery (phacoemulsification). Clinical studies have shown that this triple combination significantly improves treatment outcomes compared to using tobramycin and dexamethasone without sodium hyaluronate.
02
Targets
GR (Glucocorticoid receptor)Bacterial Ribosome
Beyond the preview
Go deeper on dexamethasone + sodium hyaluronate + tobramycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone + sodium hyaluronate + tobramycin.